Furthermore, our study showed a significant increase in serum AST levels in NASH-HCC patients by 151% compared to NASH patients, as shown in Table 1; ALT, albumin, and bilirubin showed non-significant change among both groups. This evidence concerns the gene GOT1 and hepatocellular carcinoma.